Drugs / QA108
last change Jul 2025 re-read 3 minutes ago

QA108

Developed for
age-related macular degeneration
Investigated by
Smilebiotek Zhuhai Limited

Trials 1

20262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT07189169 Jul 2025 → Mar 2027 expected age-related macular degeneration Smilebiotek Zhuhai Limited Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as QA108 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07189169 ↗